

BEST AVAILABLE COPY

U.S.S.N. 09/625,963


Filed: July 26, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION**Remarks**

Claims 1, 5, 7, 15, and 19 are pending. The specification has been amended to incorporate the proper sequence listing annotation as required by 37 C.F.R. § 1.821(d). The sequence on page 44, line 6, of the specification is present in the Sequence Listing as SEQ ID NO:3 (filed July 26, 2000). No replacement CRF of the Sequence Listing is required with this submission. There has been no new matter added to the specification.

Allowance of claims 1, 5, 7, 15, and 19 is respectfully solicited.

Respectfully submitted,



Todd S. Hoffmeister
Reg. No. P-53,029

Date: February 18, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8528
(404) 817-8588 (Fax)

ATL18564223

JC1101
078230/00017

BEST AVAILABLE COPY

U.S.S.N. 09/625,963

Filed: July 26, 2000

MARKED UP VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

Marked Up Version of Amended Specification Paragraphs**Pursuant to 37 C.F.R. § 1.121(b)(1)(iii)**

Please replace the paragraph on page 44, lines 4-6, with the following paragraph.

--In the gata-1 protein one CTL recognised peptide epitopes expressed in gata-1 expressing tumour cells was identified: Hug 378-87 HLMPFPGPLL (SEQ ID NO:3)--

ATL1 #564223 v1

ATL14564223

1C1101
078230/ 00017